Eric Hjalmar Walum

Redoxis AB focuses on preclinical drug development and validation in autoimmune diseases. The firm focuses on preclinical development of small molecules that target molecular pathways in the immunological responses associated with autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The company was founded by David Rikard Martinsson Holmdahl and Jan Peter Olofsson in 2007 and is headquartered in Gothenburg, Sweden.

Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden.

Glucox Biotech AB is a holding company. It develops clinically applicable therapeutics for treatment of type 2 diabetes; hyperglycaemia, insulin resistance and resulting complications. The firm explores new ideas for the prevention of cellular damage in ischemic stroke and heart infarction, as well the idea behind Glucox Biotech's therapies is to reduce oxidative stress by preventing the intracellular formation of reactive oxygen species. The company was founded by Ellen Mona Gratia Wilcke and Per Ingvar O. Wikström on July 1, 2003 and is headquartered in Stockholm, Sweden.